# UC San Diego

## Welcome to the 2018 D3R workshop!

# Workshop on Challenges in Docking and Screening US National Institutes of Health, 2005

Participants from pharma, academia, US government

Academic: Mike Gilson, Art Olson, Brian Shoichet

**Government:** Chris Austin, Anne Chaka, Jayne Kapur, Janna Wehrle

Pharma: Jeff Blaney, Wendy Cornell, Debbie Loughney, Cathy Peishoff, Emanuele Perola

Conclusions

Computational predictions of poses and affinities need to improve Datasets from pharma could help



Workshop report: http://bit.ly/2pLpy8C

## **Evaluation of Protein-Ligand Modeling Methods**

Tests have been run with knowledge of the experimental results

Different methods have been tested for different systems

Value of blinded, community-wide, prediction challenges



# NIH-U01 Resource, Unique Purpose

blinded prediction challenges to drive advances in CADD

#### NIH-funded initiative

CSAR 2010-2014 (Carlson, U. Michigan) D3R 2014-present (Amaro & Gilson, UC San Diego)

#### Pharma as potential source of data

highly relevant hitherto unpublished



# Drug Design Data Resource (D3R)

**Central Goal**: Utilize previously unpublished datasets as benchmarks for developers of protein-ligand modeling technologies

Synergy with Public Databases: Public release of more industrial crystal structures and affinity data

**Broader Goals**: Utilize blinded datasets to drive improvement of all CADD technologies and to foster education and dissemination of methods

#### More predictive CADD methods benefit everyone!



# **D3R Project Team**

# UC San Diego







Mike Gilson



Zied Gaieb



**Conor Parks** 



Jeff Wagner



Mike Chiu



Chris Churas



Jeff Grethe





Stephen Burley

Huanwang Yang



Jasmine Young

Chenghua Shao



# D3R Scientific Advisory Board



Aled Edwards SGC



Charles Grimshaw Takeda



David Mobley UC Irvine



John Moult U Maryland



Adrian Roitberg U Florida



Torsten Schwede Biozentrum



Martin Stahl Roche



Coherent CADD datasets

- Blinded challenges: Protein-ligand, model systems
- **Evaluation metrics**
- Capturing and disseminating workflows
- Workshops and networking



# **Challenge Types**

### Grand Challenges: ligand-protein poses and affinities

# **SAMPL:** affinities, physical properties of simpler systems with David Mobley, John Chodera, & Michael Shirts

**CELPP**: automated, weekly pose prediction challenge



# **Grand Challenges**

Stage 1: Predict poses and affinities of multiple ligands for a protein

*Stage 1b*: Release co-crystal structures without ligands to enable self-docking (Isolates evaluation of docking algorithm)

\*Co-crystal structures with ligands released\*

Stage 2: Predict affinities again

All data released, deposited to PDB, BindingDB

# Grand Challenge 2015

35 participants, 355 submissions



HSP 90: focus on potency predictions Data from Abbvie and Carlson's CSAR project 8 cocrystal structures (.6-2.0 Å resolution) 180 IC50s (5 nM-20 μM) Three series: benzimidazolones, aminopyrimidines, benzophenone-like Varied water-mediated interactions; open/closed conformations



MAP4K4: focus on pose predictions Data from Genentech 30 cocrystal structures (1.6 – 2.5 Å resolution) 18 IC50 data (3.1 nM - 10 μM) Diverse chemotypes binding in ATP site Open/closed P-loop structures

# Grand Challenge 2

#### 49 participants, 262 submissions



Farnesoid X Receptor (FXR): poses and potencies

Data from Roche 36 cocrystal structures (resolutions <2.6Å) 102 IC50s (0.3 nM-260 μM) Three series + misc: sulfonamides, benzimidazoles, spiros

Helix shifts and varied water-bridges



# Grand Challenge 3

.



#### Cathepsin S poses & IC50s

Janssen Pharmaceuticals

24 cocrystal structures, 3.0 Å 136 IC50s, 3 – 8500 nM

27 participants303 submissions

SGC-UNC/DiscoverX					
Selectivity	Activity Cliffs	Activity Cliffs	Mutations		
<b>VEGFR2</b> 85 (0.62 to >10 <sup>4</sup> nM)	<b>JAK2</b> 17 (53 to >10 <sup>4</sup> nM)	<b>TIE2</b> 18 (3.4 to >10 <sup>4</sup> nM)	<b>ABL1</b> 12 (49 to >10 <sup>4</sup> nM)		
<b>JAK2</b> 89 (0.66 to >10 <sup>4</sup> nM)					
<b>p38-α</b> 72 (0.28 to >10 <sup>4</sup> nM)					
11 participants 94 submissions	6 participants 25 submissions	6 participants 32 submissions	6 participants 11 submissions		

.

.

Kinase K<sub>d</sub>s

# **SAMPL Blinded Prediction Challenges**



Small molecule hydration free energies Nicholls, Mobley, Guthrie, Chodera, Bayly, Cooper, Pande

#### Simple model systems, e.g.,

Host-guest binding affinities Water-organic phase partition coefficients Small molecule pKa values Small molecule hydration free energies

#### Advantages vs. protein-ligand challenges

Calculations far easier to converge Troubleshooting by isolation of specific issues Reduced ambiguity (protonation states, missing residues...)



 $\beta$ -cyclodextrin

## SAMPL6 Host-Guest and pKa Challenges

Host-Guest: 124 submissions from 6 groups pKas: 95 submissions from 10 groups

Deep Cavity Cavitand Hosts Bruce Gibb, Tulane U.



#### Cucurbit[8]uril Host Lyle Isaacs, U. Maryland



Small Molecule pKas John Chodera, SKMCC





8 guest molecules with both OA and TEMOA host variants

10 guest molecules

25 compounds



## New SAMPLing Challenge





Tests efficiency of conformational sampling methods

Binding free energy convergence with Number of energy evaluations Wall clock time Total CPU time

Host-guest systems with specific setups

# Wide Range of Protein-Ligand Methods

#### Pose prediction variations

Software packages; .e.g. AutoDock Vina, Glide, rDOCK, Gold, RosettaLigand, Surflex Ligand overlay often used; e.g. ROCS, PoPSS Relaxation and rescoring; e.g. Molecular dynamics, MMPB/SA Combinations; e.g. Gold-PlantsPLP-rDock, RosettaLigand-Omega-ROCS, Surflex-Grim

#### Affinity prediction and ranking

Ligand-based Structure-based

> "Low resolution" docking and scoring "High resolution" free energy methods

#### Machine-learning



# What we have learned...

https://drugdesigndata.org/about/what-we-have-learned

Accuracy of docking and scoring correlates poorly with software choice, and successful pose prediction depends on other methodological factors; e.g.,

ligand and protein preparation choice of protein conformation treatment of xtal waters.

Pose prediction benefits from use of known ligand-protein cocrystal structures; e.g., by ligand overlay

Human inspection and intervention do not consistently improve results

Accuracy of poses used correlates poorly with scoring accuracy

Application of free energy methods to host-guest systems points to need for better force fields

Explicit solvent free energy methods have not yet outperformed faster scoring methods

Rigorous evaluation of predictions is non-trivial and can be controversial



# From Our GC Participants...

It has made me more aware of the challenges of sampling. I've been working on better ways to include this into our protocols and methods.

I would pay more attention to the receptor conformations and flexibility.

The D3R challenges allowed us to validate our docking protocol

Docking seems to be improved by machine learning and I plan to incorporate such approaches.

... it will definitely change the I do docking to avoid or minimize false positives.

It has made me pleasantly surprised when a scoring function actually delivers a useful result and makes me very skeptical of people who blindly trust the score that they get.



## **Special Issues in JCAMD** thanks to Terry Stouch, Senior Editor-in-Chief





**GC 2015** 14 articles, 2016

GC2 23 articles, 2017







SAMPL5 2/2 17 articles, 2017



## **Toward Greater Statistical Power**

#### Continuous Evaluation of Ligand Pose Predictions (CELPP)

Saturday



PDB pre-release InChIs Protein sequences Forthcoming IDs

D3R scripts Eliminate trivial ligands Pick protein structures



D3R evaluates predictions against released structures



Sunday

D3R releases InChIs and protein structures for docking

D3R opens for submissions



#### Tuesday

D3R submission window closes PDB releases structures





Method 1 OMEGA, SHAFTS, Amber11

Method 2 GLIDE-CCDC-GOLD, Amber14, MMGBSa

Method 3

WaterMap, SHAPE Screening, Structural Interaction Fingerprint, DFT/B3LYP/6-31G\*, GLIDE-SP-XP, Induced-fitdocking, Emodel/GlideScore-SP, Binding Pose Metadynamics Full description of methods

Reproducibility

Evaluation on new datasets

Application to drug design projects



## Web Portal for Data, Challenges, Community Activities



#### https://drugdesigndata.org

Thursd	ay, February 22 at Scripps Institute of Oceanography Forum (SIO)	Friday, February 23 at Scripps Institute of Oceanography Forum (SIO)		
8:15 AM	Walk or Ride Share from La Jolla Shores Hotel to SIO Breakfast on-site	8:15 AM	Walk or Ride Share from La Jolla Shores Hotel to SIO Breakfast on-site	
9:00-9:30 AM	<i>Welcome and D3R Update —</i> Mike Gilson and Rommie Amaro, D3R, UC San Diego	9:00-9:10 AM	Introduction to Day 2 — Mike Gilson and Rommie Amaro	
9:30-9:40 AM	<i>NIH Perspective</i> — Peter Lyster, NIGMS, NIH	9:10-9:40 AM	A Longitudinal View of the Grand Challenges — Pat Walters, Relay Therapeutics	
9:40-10:15 AM	Evaluation Overview of GC3 — Mill Lambert & Neysa Nevins, GSK	9:40-10:00 AM	A Longitudinal View of the SAMPL Challenges— David Mobley, UC Irvine	
10:15-10:30 AM	BREAK	10:00-10:20 AM	D3R Lessons Learned — Alexandre Bonvin, Utrecht U (Video Conference)	
10:30-10:50 AM	<i>GC3 Participant Talk 1 —</i> Maxim Totrov, MolSoft	10:20-10:40 AM	SAMPL Lessons Learned — Bogdan Iorga, ICSN, CNRS	
10:50-11:10 AM	D-11:10 AM GC3 Participant Talk 2 — Guo-wei Wei, Michigan State		BREAK	
11:10-11:30 AM	GC3 Participant Talk 3 — David Koes, University of Pittsburgh	11:00-11:20 AM	<i>Continuous Evaluation of Ligand-Protein Predictions (CELPP)</i> - Jeff Wagner, D3R, UC San Diego	
11:30-11:50 AM	<i>GC3 Participant Talk 4</i> — Ashutosh Kumar, RIKEN	11:20-11:40 AM	GC and CELPP: Workflows and Insights —Xiaoqin Zou, U. Missouri	
11:50-12:10 PM	Open Discussion on Evaluation Metrics — D3R Moderator	11:40-12:00 AM	<i>MoISSI and Workflows</i> — John Chodera, Memorial Sloan Kettering	
12:10-1:30 PM	LUNCH AT SIO	12:00-12:30 PM	Open Discussion on Enabling Adoption of Workflows	
1:30-1:40 PM	SAMPL6 Intro — John Chodera, MSKCC	12:30-1:30 PM	LUNCH AT SIO	
1:40-1:55 PM	SAMPL6 Host-Guest Intro and Overview — Andrea Rizzi, MSKCC	1:30-1:45 PM	Group Photo	
2:00-2:15 PM	<code>SAMPL6 Host-Guest Participant 1</code> — Michail Papadourakis, Edinburgh (video presentati	1:45-2:00 PM	Upcoming D3R and SAMPL Challenges—Mike Gilson, Rommie Amaro, David Mobley	
2:15-2:30 PM	SAMPL6 Host-Guest Participant 2 — Marie Laury, Washington University	2:00-2:10 PM	<i>GC3 and SAMPL6 Special Issues</i> — Terry Stouch, Journal of Computer Aided	
2:30-2:50 PM	SAMPLing Challenge Overview and Results — Andrea Rizzi, MSKCC	2:10-3:15 PM	D3R Community Feedback Discussion Datasets—Attributes, Types, Size, Number/Challenge Challenges and Workshops—Timing, Type, Frequency	
2:50-3:05 PM	BREAK			
3:05-3:25 PM	SAMPL6 pKa Intro and Overview — Mehtap Isik, MSKCC		Challenge Evaluations—Website Posting Future funding / support of blinded prediction challenges	
3:25-3:40 PM	SAMPL6 Participant 1 — Samarjeet Prasad	3:15- 3:30 PM	Wrap-up and Conclusions—Mike Gilson and Rommie Amaro	
3:40-3:55 PM	SAMPL6 Participant 2 — Qiao Zeng, NIH	3:30 PM	Workshop Concludes	
3:55-4:10 PM	SAMPL6 Participant 3— Marvin Waldman, Simulations Plus	4:00-5:00 PM	SAB Meeting (Closed Session)	
4·15-6·00 PM	Poster Session Sunset (5:30PM) with Snacks and Liquid Refreshments	5:00-5:30 PM	SAB Session with D3R PIs	
6:00 7:20 PM	7:30 PM DINNER ON THE PATIO AT SIO		SAB Dinner at La Jolla Shores Hotel	
0.00-7:50 PIVI				
7:30 PM	Walk or Ride Share Back to La Jolla Shores Hotel			



## Practicalities

#### Meals

Light breakfasts: today and tomorrow Lunch today and tomorrow Dinner today, here; on your own tomorrow

#### **Shuttles**

Both mornings 7:30am and 7:45am Thursday evening: 8:05pm and 8:15pm Friday: 3:30pm, 3:45pm and 5:30pm

**Posters:** On walls, please use blue tape provided

#### **Contact People**

Megan Murphy Iris Villanueva Anyone from the D3R team



# Acknowledgements

D3R Team at UCSD and Rutgers D3R Scientific Advisory Board SAMPL co-organizers: Profs. D. Mobley, J. Chodera, M. Shirts Dr. Terry Stouch and the JCAMD team Drs. Peter Lyster, Peter Preusch, and Janna Wehrle, National Institutes of Health Data Contributors: Janssen Pharma, SGC-UNC, Chodera Lab, Gibb Lab, Isaacs Lab, others External evaluators: Drs. Neysa Nevins, Mill Lambert, Pat Walters **All challenge participants** 

